Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Revenue:        
Contract research revenue $ 44,906 $ 104,781
Costs and Expenses:        
Research and development 2,013,063 835,308 6,711,997 2,399,595
General and administrative 1,440,141 999,803 5,264,609 3,293,233
Total costs and expenses 3,453,204 1,835,111 11,976,606 5,692,828
Loss from operations (3,408,298) (1,835,111) (11,871,825) (5,692,828)
Other income/(expense), net 13,584 (3,325) 13,354 (14,103)
Net loss (3,394,714) (1,838,436) (11,858,471) (5,706,931)
Dividend to preferred shareholders (608,343) (608,343)
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend (4,393,809) (4,393,809)
Inducement charge from exercise of warrants (16,741,356)
Net loss attributable to common shareholders $ (4,003,057) $ (6,232,245) $ (29,208,170) $ (10,100,740)
Net loss available for common shareholders per share - basic and diluted $ (0.04) $ (0.11) $ (0.33) $ (0.18)
Weighted average common shares outstanding:        
basic and diluted 92,222,601 57,628,917 89,468,153 57,505,788